Frequency of Dimethyl Fumarate-Induced Lymphopenia among Omani Patients with Multiple Sclerosis.

Autor:	Jaboob A; Department of Medicine, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman.; Department of Medicine, Sultan Qaboos University, Muscat, Oman., Asmi AA; Department of Medicine, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman., Islam MM; Department of Statistics, College of Science, Sultan Qaboos University, Muscat, Oman., Rezvi S; Department of Family Medicine & Public Health, Sultan Qaboos University, Muscat, Oman., Redha I; Neurology Department, Khoula Hospital, Muscat, Oman., Al-Khabouri J; Neurology Department, Khoula Hospital, Muscat, Oman., Al-Zakwani I; Department of Pharmacy, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman.; Department of Pharmacology & Clinical Pharmacy, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman., Al-Qassabi A; Department of Medicine, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman.; Department of Medicine, Sultan Qaboos University, Muscat, Oman., Al-Abri H; Department of Medicine, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman.; Department of Medicine, Sultan Qaboos University, Muscat, Oman.; Neurology Department, Khoula Hospital, Muscat, Oman., Gujjar AR; Department of Medicine, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman.; Department of Medicine, Sultan Qaboos University, Muscat, Oman.
Jazyk:	angličtina
Zdroj:	Sultan Qaboos University medical journal [Sultan Qaboos Univ Med J] 2024 Feb; Vol. 24 (1), pp. 44-51. Date of Electronic Publication: 2024 Feb 28.
DOI:	10.18295/squmj.9.2023.051
Abstrakt:	Objectives: Dimethyl fumarate (DMF) is known to cause lymphopenia when used to treat patients with multiple sclerosis (MS). However, research on DMF therapy in the Arab world, especially in Oman, is scarce. This study aimed to analyse the prevalence of lymphopenia among Omani patients with MS and their reasons for discontinuing DMF therapy. Methods: In this retrospective study, the medical records of Omani patients with MS who were treated using DMF at two tertiary hospitals in Muscat, Oman, from February 2017 to February 2023 were reviewed. Their demographic, clinical and laboratory data were retrieved and analysed. Absolute lymphocyte count values at baseline and at the last follow-up, as well as the reasons for discontinuing DMF therapy, were collected. Descriptive and inferential statistical techniques were used for data analysis. Binary-logistic regression analysis was used to identify the risk factors for DMF-induced lymphopenia. Results: A total of 64 Omani patients with MS were included in this study. The majority of the study participants (n = 40; 63%) were female. All included patients started DMF therapy at the mean age of 33 ± 7.7 years. After administration of DMF, 14 (21.9%) patients developed grades 1-3 of lymphopenia. The DMF therapy was discontinued for 23 (36.0%) patients, mainly in response to adverse events or confirmed pregnancy. Female gender was the only significant predictor of DMF-induced lymphopenia ( P = 0.037). Conclusions: Most Omani patients with MS had mild lymphopenia (grades 1-2). Early adverse events and pregnancy were the main reasons provided for discontinuing DMF therapy. Competing Interests: CONFLICTS OF INTEREST: AAA received honoraria as a speaker from Novartis, Sanofi, Biologix, Merck, Roche, Biogen and Bayer. AAA serves on the scientific advisory boards of Novartis, Merck and Roche. JAK received honoraria as a speaker from Merck, Sanofi, Novartis, Roche and Biogen. JAK serves on the scientific advisory boards of Novartis, Merck and Sanofi. JAK is participating in a phase 3 trial for Novartis. AAQ received honoraria as a speaker from Novartis and AbbVie. (© Copyright 2024, Sultan Qaboos University Medical Journal, All Rights Reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF